With a race on to develop a new obesity treatment, Ipsos surveyed primary care doctors and found receptivity to all three clinical-stage products.
Between one-half and two-thirds of PCPs said they would likely prescribe any of the three drugs to treat their obese or overweight patients: Qnexa from Vivus, Lorqess/lorcaserin from Arena Pharmaceuticals or Contrave, from Orexigen Therapeutics.
The results were derived from an Ipsos online survey conducted as part of a Vantis Health Files (VHF) project in April 2010 among 1,500 (> 125 exposures per product) PCPs. VHF is a syndicated service designed to provide insights into the market potential for new healthcare products.
Among the three candidates, slated for FDA review within the next few months, Ipsos forecasted US retail sales to exceed $400 million annually within three to five years of launch and that Lorqess/lorcaserin has the best chance of approval.